Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population (OPERA-1)
A US-Prospective, Registry-Based, Observational, Exposure Cohort Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
Sponsor: Incyte Corporation
A observational or N/A phase clinical study on Atopic Dermatitis and Pregnancy Related, this trial is actively recruiting participants. The trial is conducted by Incyte Corporation and has accumulated 7 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Recruiting
-
Aug 2025 — Jan 2026 [monthly]
Recruiting
-
Jan 2025 — Aug 2025 [monthly]
Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Recruiting
First recorded
Sep 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .